Early pregnancy interruption with a single PGF2 alpha 15-methyl-analogue vaginal suppository

Pregnancy was interrupted successfully in 70% of 20 early pregnancies, 35-49 days in duration as dated from the first day of the last menstrual period, by administration of a single intravaginal suppository containing 3 mg of (15S)-15-methyl prostaglandin F2 alpha (PGF2 alpha). No correlation could be demonstrated with baseline beta-subunit human chorionic gonadotropin or serum levels of prostaglandin obtained within ten hours of treatment. Continued pregnancy was documented in 10%. The rate of failures and the frequency of gastrointestinal side effects were deemed too great to warrant adopting this agent for clinical usage.